Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2763)	12/15/2010 9:41:11 PM
From: Jibacoa	Respond to of 3722

THLD was up 29.82% at its intraday H at 12.05pm, it closed up 15.79% and did OK AHs.<g> bigcharts.marketwatch.com But what was really more impressive with THLD today was its trading volume, which was 5487% of its ADV. Volume has significantly increased this week in spite of no obvious news, suggesting that something is cooking or some news could be coming.<g> Its last public announcement was the poster presented in Berlin last month concerning some results of TH-302, its hypoxia-activated prodrug. Those results suggested that TH-302 behaved as designed with broad activity against multiple tumor types and in all combinations with which it was evaluated,it was well-tolerated and the activity seen in all combinations used, was greater than what would had been expected from any of the individual chemotherapy agents alone. <g> It has been over a year since their agreement with Eleison for further clinical development of glufosfamide. Under the agreement, Eleison is responsible for the development, manufacturing and marketing of the drug and THLD will share in the profits if the drug is approved.<g> It has now been more than eight years since they licensed 2DG from Drs. Lampidis and Priebe.<g> There has been recently some interest regarding the onset of type2 DM in patients with pancreatic Ca, and the possibility of a pancreatic neoplasm should be considered in all cases of new onset of type2 DM. Resection of tumors have also shown improvement or eliminated the DM. <g> The possible use of 2DG in the chemotherapy of pancreatic Cas, alone or in combination with other agents or its radioactive form still will require further investigation. The trials on patients in Miami and San Antonio, were reported in 2007 biomed.miami.edu Other trials in Iowa were reported in Feb2008 ncbi.nlm.nih.gov As previously mentioned, the ACTAY is $3 And with some good news the stock has plenty of room to run.<g> bigcharts.marketwatch.com Bernard